New combo therapy shows promise for tough esophageal cancer
NCT ID NCT06885814
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug (adebrelimab) combined with standard chemotherapy and radiation for people with advanced or returning esophageal cancer that cannot be removed by surgery. The goal is to see if this combination can shrink or control the cancer better. Thirty adults aged 18-75 will receive the treatment and be monitored for side effects and outcomes like tumor response and survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nanfang Hospital, Southern Medical University
RECRUITINGGuangzhou, Guangdong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a new drug rally the immune system against Hard-to-Treat cancers?
- AI biomarker may reveal who responds to esophageal cancer immunotherapy
- Can a single Protein's mutations predict esophageal cancer outcomes?
- A sponge you swallow could detect esophageal cancer before it spreads